Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Lehmann

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Cancer|September 21, 2004
The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinomaJan Lehmann, Margitta Retz, Nils Nürnberg, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 13, 2008
Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experienceHenrik Suttmann, Aleksandar Grgic, Jan Lehmann, et al.
Nature Communications|February 21, 2026
Non-hydrolyzable acetyllysine analogs to study protein acetylation in vitro and in cellsSimon Maria Kienle, Matthias Sigg, Tobias Schneider, et al.
BMC Cancer|April 15, 2011
Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancerIver Nordentoft, Lars Dyrskjøt, Julie S Bødker, et al.
Journal of Cancer Survivorship : Research and Practice|April 24, 2024
Long-term quality of life of testicular cancer survivors differs according to applied adjuvant treatment and tumour typeJulia Heinzelbecker, Karla Kaßmann, Simone Ernst, et al.
BMC Infectious Diseases|September 20, 2002
Expression of human beta-defensins 1 and 2 in kidneys with chronic bacterial infectionJan Lehmann, Margitta Retz, Jürgen Harder, et al.
Aktuelle Urologie|September 24, 2020
[CARD study: relevance for the treatment of advanced prostate cancer]Axel S Merseburger, Andreas Bannowsky, Klaus Becker, et al.
Journal of Cancer Research and Clinical Oncology|March 4, 2015
Functional analyses and prognostic significance of SFRP1 expression in bladder cancerAnja Rogler, Emil Kendziorra, Johannes Giedl, et al.
Neoplasia (New York, N.Y.)|August 7, 2010
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapyAndreas-Claudius Hoffmann, Peter Wild, Christina Leicht, et al.
International Journal of Cancer|November 13, 2004
CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cellsMargitta M Retz, Sukhvinder S Sidhu, Ekaterina Blaveri, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Cancer|September 21, 2004
The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinomaJan Lehmann, Margitta Retz, Nils Nürnberg, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 13, 2008
Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experienceHenrik Suttmann, Aleksandar Grgic, Jan Lehmann, et al.
Nature Communications|February 21, 2026
Non-hydrolyzable acetyllysine analogs to study protein acetylation in vitro and in cellsSimon Maria Kienle, Matthias Sigg, Tobias Schneider, et al.
BMC Cancer|April 15, 2011
Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancerIver Nordentoft, Lars Dyrskjøt, Julie S Bødker, et al.
Journal of Cancer Survivorship : Research and Practice|April 24, 2024
Long-term quality of life of testicular cancer survivors differs according to applied adjuvant treatment and tumour typeJulia Heinzelbecker, Karla Kaßmann, Simone Ernst, et al.
BMC Infectious Diseases|September 20, 2002
Expression of human beta-defensins 1 and 2 in kidneys with chronic bacterial infectionJan Lehmann, Margitta Retz, Jürgen Harder, et al.
Aktuelle Urologie|September 24, 2020
[CARD study: relevance for the treatment of advanced prostate cancer]Axel S Merseburger, Andreas Bannowsky, Klaus Becker, et al.
Journal of Cancer Research and Clinical Oncology|March 4, 2015
Functional analyses and prognostic significance of SFRP1 expression in bladder cancerAnja Rogler, Emil Kendziorra, Johannes Giedl, et al.
Neoplasia (New York, N.Y.)|August 7, 2010
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapyAndreas-Claudius Hoffmann, Peter Wild, Christina Leicht, et al.
International Journal of Cancer|November 13, 2004
CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cellsMargitta M Retz, Sukhvinder S Sidhu, Ekaterina Blaveri, et al.
Pageof 6